Elafibranor

Elafibranor (GFT505) is a synthetic phenoxyalkanoic acid derivative and dual agonist of the peroxisome proliferator-activated receptor alpha (PPARalpha) and peroxisome proliferator-activated receptor delta (PPARdelta), with additional lower-potency agonist activity at the peroxisome proliferator-activated receptor gamma (PPARgamma). The compound activates PPARalpha with an EC50 of approximately 45 nanomolar and PPARdelta with an EC50 of approximately 175 nanomolar, producing a composite pharmacological profile that modulates hepatic fatty acid beta-oxidation, triglyceride metabolism, high-density lipoprotein cholesterol, bile acid synthesis and transport, glucose homeostasis, and macrophage-mediated hepatic inflammation through coordinated transcriptional regulation at both receptor subtypes. Elafibranor and its principal active metabolite GFT1007, formed by hydrolysis of the parent compound, both contribute to the pharmacological activity. The compound was discovered and initially developed by Genfit S.A. (Lille, France) for the treatment of nonalcoholic steatohepatitis (NASH), advancing through a Phase 2b trial (GOLDEN-505) in 274 patients that produced a post-hoc signal for NASH resolution without fibrosis worsening at the 120 mg dose, and into the Phase 3 RESOLVE-IT trial in over 1,000 patients, which was terminated in 2020 following an interim futility analysis that failed to demonstrate statistically significant separation from placebo on the primary endpoint. Development subsequently pivoted to primary biliary cholangitis (PBC), where elafibranor received FDA Breakthrough Therapy Designation in 2019 and demonstrated robust efficacy in the Phase 3 ELATIVE trial: 51 percent of patients receiving elafibranor 80 mg achieved a biochemical cholestasis response at week 52, compared to 4 percent on placebo, with alkaline phosphatase normalization in 15 percent of treated patients versus none on placebo. On June 10, 2024, the United States Food and Drug Administration granted accelerated approval to elafibranor (trade name Iqirvo, marketed by Ipsen) for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. European Union authorization followed in September 2024, and the United Kingdom National Institute for Health and Care Excellence (NICE) recommended elafibranor for National Health Service use in October 2024. Pharmacokinetics are characterized by high plasma protein binding (approximately 99.7 percent), a large apparent volume of distribution (approximately 4,731 liters), a long elimination half-life of the parent compound (approximately 60 to 70 hours), and metabolism of GFT1007 through CYP2C8, UGT1A3, and UGT2B7. The compound is generally well tolerated at the approved 80 mg dose; the principal adverse events in controlled trials were gastrointestinal (abdominal pain, diarrhea, nausea, and vomiting, each occurring in approximately 11 percent of treated patients versus 2 to 9 percent on placebo), weight gain, arthralgia, and musculoskeletal complaints including rare myopathy and rhabdomyolysis. Dose-dependent hepatotoxicity has been observed at supratherapeutic doses (exceeding 120 mg), with transaminase elevations above 5 times the upper limit of normal in approximately one-third of healthy volunteers at those exposures. The compound is contraindicated in decompensated cirrhosis and complete biliary obstruction and carries a warning for embryo-fetal toxicity. This monograph reviews the chemistry, synthesis, and structural class of elafibranor; the PPAR-mediated molecular pharmacology; the comprehensive pharmacokinetic profile including the GFT1007 active metabolite; the preclinical evidence in rodent models of steatohepatitis, fibrosis, and cholestasis; the clinical evidence base across NASH and PBC indications; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five alternative agents (obeticholic acid, seladelpar, bezafibrate, fenofibrate, and saroglitazar) against elafibranor on five competency standards.